$ADPT

Adaptive Biotechnologies Corp

Adaptive Biotechnologies is a biotechnology company that uses proprietary sequencing, computational biology and machine learning technologies to study the adaptive immune system and develop clinical products and services. It serves clinicians, patients and biopharmaceutical companies through two businesses: MRD and Immune Medicine. The MRD business offers clonoSEQ, an NGS assay that measures minimal residual disease in lymphoid malignancies. Clinicians use the clonoSEQ diagnostic testing service to detect and monitor cancer cells, while biopharmaceutical partners use the assay in clinical trials and drug development. The Immune Medicine business provides immune receptor sequencing services, licenses proprietary data, offers TCR-antigen prediction models and supports target discovery for research and development partners. Adaptive Biotechnologies is headquartered in Seattle, Washington.

AlphAI earnings readThird Quarter 2026 · NOV 4Adaptive Biotechnologies Reports Third Quarter 2026 Financial ResultsVerdict: mixed

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

0
0
1
—
$6.5M
RUBINSTEIN JULIE
100%
See all $ADPT insider activity →

RUBINSTEIN JULIE sold $1.0M of ADPT

RUBINSTEIN JULIE (President and COO) sold 35,228 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $29.73 ($28.93–$31.22, $1.05M total) across 4 trades over 2026-11-11 to 2026-11-13 under a Rule 10b5-1 trading plan.

RUBINSTEIN JULIE sold $709K of ADPT

RUBINSTEIN JULIE (President and COO) sold 23,762 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $29.82 ($28.87–$30.58, $0.71M total) across 5 trades over 2026-11-09 to 2026-11-10 under a Rule 10b5-1 trading plan.

ADPT sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 1 news story mentioning ADPT (Adaptive Biotechnologies Corp). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.

Recent ADPT coverage spans insider activity, earnings and corporate actions.

In the last 30 days, ADPT insiders filed 38 SEC Form 4 transactions — no purchases and 38 sales ($6.5M). The most active reporter was RUBINSTEIN JULIE, President and COO, with 37 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.

What's driving ADPT

AlphAI scores every news story that mentions ADPT with an AI model for sentiment and relevance, and aggregates insider trades from Adaptive Biotechnologies Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ADPT

Score
$ADPTHighAI 8/10Earnings

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

Adaptive Biotechnologies Corp (ADPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results SEATTLE, Nov. 04, 2026 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genet

Adaptive Biotechnologies Corp. (ADPT) Rallies on Earnings Beat, Raised Outlook, and Cash-Flow Targets

Adaptive Biotechnologies (ADPT) reported stronger-than-expected Q3 2026 results, raised its outlook, and reaffirmed profitability expectations. The company's stock has surged 65.73% year-to-date, closing at $26.92 on October 26, 2026. Alger Small Cap Growth Fund highlighted ADPT's diagnostic tools, including clonoSEQ, which was referenced in clinical guidelines for monitoring multiple myeloma.

Related tickers